Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis - 16/08/18
Doi : 10.1016/j.jaad.2018.03.008
Alice B. Gottlieb, MD, PhD a, ⁎ 
, Kim A. Papp, MD, PhD, FRCPC b, Charles A. Birbara, MD c, Catherine L. Shuler, MS d, Russel Burge, PhD d, Janelle Erickson, PhD d, Lisa Kerr, MSPH d, Philip J. Mease, MD e
, Kim A. Papp, MD, PhD, FRCPC b, Charles A. Birbara, MD c, Catherine L. Shuler, MS d, Russel Burge, PhD d, Janelle Erickson, PhD d, Lisa Kerr, MSPH d, Philip J. Mease, MD e a Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, New York
b K Papp Clinical Research and Probity Medical Research, Waterloo, Ontario
c Department of Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts
d Eli Lilly and Company, Indianapolis, Indiana
e Department of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and University of Washington School of Medicine, Seattle, Washington
∗Correspondence to: Alice B. Gottlieb, MD, PhD, New York Medical College, Department of Dermatology, Metropolitan Hospital, 1901 First Ave, New York, NY 10029New York Medical CollegeDepartment of DermatologyMetropolitan Hospital1901 First AveNew YorkNY10029
| Funding sources: Supported by Eli Lilly and Company. |
|
| Conflicts of interest: Dr Gottlieb has received honoraria for her role as a consultant, speaker, and/or advisory board member for Janssen, Inc, Celgene Corporation, Bristol-Myers Squibb Company, Beiersdorf Inc, AbbVie, UCB, Novartis, Incyte, Eli Lilly and Company, Reddy Labs, Valeant, Dermira, Allergan, and Sun Pharmaceutical Industries. Dr Gottlieb also received research and educational grants for her role as a Principal Investigator for Janssen and Incyte. Dr Papp has received honoraria and research grants for his role as a consultant, speaker, Scientific Officer, steering committee member, or advisory board member for AbbVie, Akros, Allergan, Amgen, Anacor, Astellas, AstraZeneca, Baxalta, Boehringer Ingelheim, Bristol-Meyers Squibb Company, CanFite, Celgene Corporation, Dermira, Devonian, Dow Pharma, Eli Lilly and Company, Galderma, Genentech, GSK, Janssen, Kyowa Hakko Kirin, Leo, MedImmune, Meiji Seika Pharma, Merck, Merck-Serono, Mitsubishi Pharma, Mylan, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Stiefel, Takeda, UCB, and Valeant. Dr Birbara has received compensation for his role as a Principal Investigator. Ms Shuler, Dr Burge, Dr Erickson, and Ms Kerr are all employees of Eli Lilly and Company and may own company stock or stock options. Dr Mease has received honoraria and research grants for his role as a consultant, speaker, or Principal Investigator for AbbVie, Amgen, Bristol-Meyers Squibb Company, Celgene Corporation, Genentech, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun Pharmaceuticals Industries, and UCB. |
|
| Previously presented: This work was presented in part at the European Academy of Dermatology Venereology Congress 2015, Copenhagen, Denmark, on October 7-11, 2015; and at the International Federation of Psoriasis Association's 4th World Psoriasis and Psoriatic Arthritis Conference 2015, Stockholm, Sweden, on July 8-11, 2015. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 3
P. 593-595 - septembre 2018 Retour au numéro
Article précédent
- Bioimpedance measurement as an assessment of margin positivity in Mohs surgical specimens of nonmelanoma skin cancer: Management implications
- Ryan M. Svoboda, Manish J. Gharia, John Shell, William D. Gregory
- Ethical challenges with treating nonadherent patients in a group practice setting
- Benjamin Freemyer, Benjamin Stoff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?